Compare Equinix Inc (EQIX) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Illumina, Inc. — how do they compare? Equinix Inc trades at $1,011.13 (market cap $101.81B), while Illumina, Inc. trades at $264.24 (market cap $40.43B). The key difference: Equinix Inc is far larger — about 2.5× Illumina, Inc.'s market cap, and Equinix Inc pays a 2% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Illumina, Inc. for 83 Days on average.
| EQIX | ILMN | |
|---|---|---|
Market Cap | $101.81B | $40.43B |
Volume | 442,874 | 2,948,626 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $293.69 |
52-Week Low | $726.09 | $91.00 |
Typical Hold Time | 110 Days | 83 Days |
Enterprise Value | $122.94B | $41.79B |
Dividend Yield | 2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,031.77, down 1.49% today, with strong analyst support (75% buy ratings) and a $1,250 consensus price target. The stock shows bullish technical signals with support at $1,025 and resistance at $1,042. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 and Q4 2025 missing. The company maintains robust revenue growth, expanding from $7.3B in 2022 to $9.2B in 2025, with net income margins improving to 14.64%. AI-driven data center demand is accelerating growth, with Equinix planning $5B-$7B annual investments.
Outlook remains positive due to strong AI infrastructure demand and interconnection growth, though elevated valuation ratios (P/E 66.39) and significant capital expenditures pose risks. Debt levels have risen, with debt-to-asset ratio increasing to 47.13% in 2025. The upcoming Q3 2026 earnings on October 28 will be critical for validating growth trajectory amid competitive pressures.
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
